https://primates.life/members/peter-attia/activity/ Activity feed for Peter Attia. Mon, 17 Aug 2026 08:15:00 -0700 https://buddypress.org/?v= en-US 30 hourly 2 d67960ef877905a355ec869940e87cb9 https://primates.life/?p=85077 Mon, 17 Aug 2026 04:15:00 -0700 #404 ‒ Mental health beyond neurotransmitters: the role of hormones in psychiatry, why symptom reduction isn’t enough, and the future of psychedelic therapies | Linus Abrams, M.D.View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter In this episode, Peter sits down with Dr. Linus Abrams, a psychiatrist with nearly 35 years of clinical experience specializing in mood disorders and psychopharmacology, to explore how our understanding of mental health is evolving beyond the traditional neurotransmitter model. After decades in practice, Linus began questioning many of the assumptions underlying modern psychiatry, leading him to investigate how hormones, metabolism, inflammation, circadian biology, and the endocrine system shape mood and cognition. Together, Peter and Linus examine why psychiatric care should aim not only to reduce symptoms but also to restore the full human experience. They discuss how psychiatric medications work, where they fall short, and why distinguishing bipolar disorder from unipolar depression is essential for effective treatment. The conversation also explores the growing mental health burden of social isolationn associated with digital devices and social media, along with the biological factors—nutrition, exercise, sleep, and chronic stress—that influence resilience and distress tolerance. Linus explains the powerful roles of estrogen, progesterone, testosterone, and thyroid hormone in regulating mood and cognition across the lifespan. Finally, Peter and Linus review the promise and limitations of ketamine and psychedelic therapies, and why the future of psychiatry may lie in integrating neuroscience, endocrinology, and whole-body physiology to better understand, diagnose, and treat mental illness. We discuss: Linus’s passion for understanding his patients and going beyond traditional psychiatry [2:45]; A short primer on the different classes of drugs used in psychiatry [12:45]; Evaluation of a patient with bipolar disorder [26:00]; An evolutionary perspective on depression [33:30]; Changes in the modern world triggering mental health problems [41:00]; An evolutionary perspective on insomnia [48:15]; Peter’s window analogy to understand distress tolerance and irritability [49:45]; The impact of foundational biological factors on psychiatry: nutrition, exercise, sleep, and endocrinology [52:30]; The effect of estradiol on neurotransmitters in the brain [58:15]; Options for increasing testosterone in men, and why clomiphene is inferior to exogenous testosterone [1:11:00]; The rapid drop in progesterone is linked to both premenstrual dysphoric disorder (PMDD) and postpartum depression [1:14:30]; Treatment of postpartum depression [1:18:00]; Hypothyroidism presenting as depression: how Linus makes the diagnosis and what he uses for treatment [1:26:00]; The link between hyperarousal and chronically elevated cortisol [1:39:30]; A case where the menopause transition uncovers bipolar disorder [1:44:15]; Ketamine as a tool to treat recalcitrant depression, and concerns about its recreational use [1:49:15]; Case study: an Alzheimer’s patient who improved after psilocybin, and why Linus is cautious about drawing conclusions from it [1:55:15]; Peter’s experience with psychedelics, and the myth that estrogen is bad for men [2:00:30]; The therapeutic potential of psychedelics in psychiatry [2:11:00]; and More. Connect With Peter on Twitter, Instagram, Fa […]

]]> 313c7c4d8b4e7e61a6d4c91bd3157c55 https://primates.life/?p=75719 Mon, 10 Aug 2026 04:15:00 -0700 #403 ‒ Peptides: separating scientific promise from marketing hypeView the Show Notes Page for This Episode Become a Member to Receive Exclusive Content […]

]]> 313c7c4d8b4e7e61a6d4c91bd3157c55 https://primates.life/?p=75718 Mon, 10 Aug 2026 04:15:00 -0700 #403 ‒ Peptides: separating scientific promise from marketing hypeView the Show Notes Page for This Episode Become a Member to Receive Exclusive Content […]

]]> 235a8d02e3dd6939b67d32d97cb73f35 https://primates.life/?p=75721 Mon, 03 Aug 2026 04:15:00 -0700 #402 ‒ NMR blood analysis: how heart disease risk, insulin resistance, inflammation, and mortality risk can be assessed from a single blood sample | Jim Otvos, Ph.D.View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter Jim Otvos is a biophysical chemist who pioneered the use of nuclear magnetic resonance (NMR) spectroscopy to measure lipoprotein particles and developed the first FDA-cleared method for directly quantifying LDL particle number (LDL-P), a technology that has since expanded to provide broader insights into metabolic health, inflammation, insulin resistance, and mortality risk. In this episode, Jim recounts the unlikely story of transforming a flawed cancer test into a new way of measuring lipoproteins, explains what standard cholesterol tests can miss and why LDL-P and apoB can inform treatment decisions beyond LDL cholesterol alone, and dispels the misconception that large, “fluffy” LDL particles are benign. He also explores how NMR can reveal insulin resistance before blood sugar rises, GlycA as a marker of chronic low-grade inflammation, and the metabolic vulnerability index (MVX) as a potential measure of frailty, resilience, and mortality risk across the lifespan. Finally, Jim explains why NMR diagnostics remain underused despite the wealth of information they can extract from a single blood test. We discuss: How investigating a flawed 1986 cancer test led to the development of NMR (nuclear magnetic resonance) lipoprotein testing [3:30]; How standard lipid panels measure cholesterol and triglycerides, and why LDL cholesterol is estimated rather than directly measured [15:15]; How NMR spectroscopy measures lipoprotein particle size and concentration [20:30]; Why LDL particle number matters more than particle size, and why large, “fluffy” LDL is not benign [28:45]; Discordance between LDL cholesterol and LDL particle number: which measure better reflects cardiovascular risk? [36:30]; How metabolic syndrome and lipid-lowering treatment contribute to the discordance between LDL-C and LDL-P, and the value of particle number for managing risk [45:30]; Using the NMR-derived LP-IR score to detect insulin resistance and predict type 2 diabetes before glucose rises [51:15]; The development, commercialization, and uncertain future of the Vantera NMR Analyzer and NMR-based diagnostics [1:04:45]; The analytical efficiency of NMR testing and the data-driven development of the Metabolic Vulnerability Index (MVX) [1:16:00]; GlycA as an NMR-derived marker of systemic inflammation: its discovery, biological basis, and advantages over hs-CRP [1:25:45]; Developing the Metabolic Vulnerability Index (MVX): biomarkers of inflammation, malnutrition, muscle wasting, and mortality risk [1:34:00]; What MVX can tell us about longevity and mortality [1:44:15]; How MVX may reveal metabolic frailty and predict premature mortality decades in advance in young, healthy adults [1:50:30]; Potential applications of MVX for predicting treatment response, surgical resilience, and clinical trial outcomes, and the barriers to broader use [2:00:00]; ApoB versus LDL-P: their clinical similarities, the additional information provided by NMR, and barriers to broader adoption [2:07:30]; Interpreting the effects of the CETP inhibitor, obicetrapib, on LDL-P, apoB, and small HDL particles [2:13:00]; The future of NMR diagnostics and MVX: translating scientific potential into broader clinical use [2:20:45]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTu […]

]]> 235a8d02e3dd6939b67d32d97cb73f35 https://primates.life/?p=75720 Mon, 03 Aug 2026 04:15:00 -0700 #402 ‒ NMR blood analysis: how heart disease risk, insulin resistance, inflammation, and mortality risk can be assessed from a single blood sample | Jim Otvos, Ph.D.View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter Jim Otvos is a biophysical chemist who pioneered the use of nuclear magnetic resonance (NMR) spectroscopy to measure lipoprotein particles and developed the first FDA-cleared method for directly quantifying LDL particle number (LDL-P), a technology that has since expanded to provide broader insights into metabolic health, inflammation, insulin resistance, and mortality risk. In this episode, Jim recounts the unlikely story of transforming a flawed cancer test into a new way of measuring lipoproteins, explains what standard cholesterol tests can miss and why LDL-P and apoB can inform treatment decisions beyond LDL cholesterol alone, and dispels the misconception that large, “fluffy” LDL particles are benign. He also explores how NMR can reveal insulin resistance before blood sugar rises, GlycA as a marker of chronic low-grade inflammation, and the metabolic vulnerability index (MVX) as a potential measure of frailty, resilience, and mortality risk across the lifespan. Finally, Jim explains why NMR diagnostics remain underused despite the wealth of information they can extract from a single blood test. We discuss: How investigating a flawed 1986 cancer test led to the development of NMR (nuclear magnetic resonance) lipoprotein testing [3:30]; How standard lipid panels measure cholesterol and triglycerides, and why LDL cholesterol is estimated rather than directly measured [15:15]; How NMR spectroscopy measures lipoprotein particle size and concentration [20:30]; Why LDL particle number matters more than particle size, and why large, “fluffy” LDL is not benign [28:45]; Discordance between LDL cholesterol and LDL particle number: which measure better reflects cardiovascular risk? [36:30]; How metabolic syndrome and lipid-lowering treatment contribute to the discordance between LDL-C and LDL-P, and the value of particle number for managing risk [45:30]; Using the NMR-derived LP-IR score to detect insulin resistance and predict type 2 diabetes before glucose rises [51:15]; The development, commercialization, and uncertain future of the Vantera NMR Analyzer and NMR-based diagnostics [1:04:45]; The analytical efficiency of NMR testing and the data-driven development of the Metabolic Vulnerability Index (MVX) [1:16:00]; GlycA as an NMR-derived marker of systemic inflammation: its discovery, biological basis, and advantages over hs-CRP [1:25:45]; Developing the Metabolic Vulnerability Index (MVX): biomarkers of inflammation, malnutrition, muscle wasting, and mortality risk [1:34:00]; What MVX can tell us about longevity and mortality [1:44:15]; How MVX may reveal metabolic frailty and predict premature mortality decades in advance in young, healthy adults [1:50:30]; Potential applications of MVX for predicting treatment response, surgical resilience, and clinical trial outcomes, and the barriers to broader use [2:00:00]; ApoB versus LDL-P: their clinical similarities, the additional information provided by NMR, and barriers to broader adoption [2:07:30]; Interpreting the effects of the CETP inhibitor, obicetrapib, on LDL-P, apoB, and small HDL particles [2:13:00]; The future of NMR diagnostics and MVX: translating scientific potential into broader clinical use [2:20:45]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTu […]

]]> e4a15f5805fe30b1c0f1e56db5be010a https://primates.life/?p=75722 Mon, 27 Jul 2026 04:15:00 -0700 #401 ‒ How curiosity transforms medicine: extraordinary discoveries that changed modern healthcareView the Show Notes Page for This Episode Become a Member […]

]]> e4a15f5805fe30b1c0f1e56db5be010a https://primates.life/?p=75723 Mon, 27 Jul 2026 04:15:00 -0700 #401 ‒ How curiosity transforms medicine: extraordinary discoveries that changed modern healthcareView the Show Notes Page for This Episode Become a Member […]

]]> 2de7f7798f7f153f27518c036c81ab55 https://primates.life/?p=75725 Mon, 20 Jul 2026 04:15:00 -0700 #400 ‒ AMA #87: Environmental pollution and longevity: air pollution, noise, light, EMFs, and practical strategies to mitigate health risksView the Show Notes […]

]]> 2de7f7798f7f153f27518c036c81ab55 https://primates.life/?p=75724 Mon, 20 Jul 2026 04:15:00 -0700 #400 ‒ AMA #87: Environmental pollution and longevity: air pollution, noise, light, EMFs, and practical strategies to mitigate health risksView the Show Notes […]

]]> b390f57f8c0edf23b4c46184bc9e38fe https://primates.life/?p=75727 Mon, 13 Jul 2026 04:15:00 -0700 #399 ‒ The evolution of Alzheimer’s disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter Gayatri Devi is a nationally recognized neurologist specializing in memory disorders, including Alzheimer’s disease and related dementias. In this episode, Gayatri explains how to think about dementia as a spectrum—including Alzheimer’s disease, vascular dementia, Lewy body dementia, and mixed presentations—while exploring the evolving biology of amyloid, tau, and neuroinflammation and why brain pathology does not always correlate with symptoms. She discusses her approach to detecting subtle cognitive decline in high-functioning individuals, the role of biomarkers and APOE4 testing in asymptomatic patients, the benefits and risks of anti-amyloid therapies such as lecanemab and donanemab, and strategies for minimizing treatment-related complications. Gayatri also examines why some patients may stabilize or even improve with individualized care, the overlap among different dementia syndromes, and the relationship between menopause, estrogen, and cognition—including her concept of menopause-related cognitive impairment. Finally, she discusses how advances in early detection, AI-assisted monitoring, targeted therapies, and precision medicine are reshaping the future of dementia care. We discuss: Gayatri’s training and clinical focus, why dementia is a spectrum disease, and how personalized treatment is changing Alzheimer’s care [3:45]; How Alzheimer’s disease fits within the broader spectrum of dementia: diagnosis, biomarkers, and early pathophysiology [7:15]; The emerging role of neuroinflammation and viral infections in Alzheimer’s disease [13:30]; Gayatri’s comprehensive approach to evaluating cognitive decline in high-functioning patients [17:45]; Why forgetting names is usually normal and when word-finding problems become concerning [29:00]; Why women are at higher risk for Alzheimer’s disease and how menopause influences cognition [33:45]; The promise and limitations of blood-based biomarkers for diagnosing Alzheimer’s disease [40:15]; When preclinical Alzheimer’s screening is appropriate and how to interpret positive biomarker results [45:00]; Case study: early Alzheimer’s prevention in a highly-functional woman in her 50s with two copies of APOE4 [47:15]; Anti-amyloid therapies: balancing clinical benefit with ARIA risk using slow titration [51:45]; The aducanumab controversy, why it was discontinued, and why Gayatri would still choose it [1:00:00]; How anti-amyloid therapies cause ARIA, strategies for detecting and managing these complications, and how future therapies may improve safety and accessibility [1:03:30]; Two patient examples of exceptional responses to anti-amyloid therapy [1:12:30]; A multimodal approach to Alzheimer’s treatment: combination therapy, MRI-guided TMS, GLP-1 receptor agonists, and more [1:15:00]; Vascular dementia, Lewy body dementia, and the overlap with Alzheimer’s disease [1:21:00]; Lewy body dementia and Parkinson’s disease: distinguishing two alpha-synuclein disorders [1:26:45]; Risk factors for Lewy body dementia and what remains unknown [1:36:15]; Treating menopause-related cognitive impairment: hormone therapy, brain rehabilitation, and balancing breast cancer risk [1:38:45]; How biomarkers changed Gayatri’s perspective on the potential for Alzheimer’s patients to improve [1:47:15]; The future of Alzheimer’s care: AI, precision medicine, and personalized treatment [1:49:30]; and More. Connect With Peter on Twitter, […]

]]> e32bba47b35bb59fa522a005dd0def99 https://primates.life/?p=75726 Mon, 13 Jul 2026 04:15:00 -0700 #399 ‒ The evolution of Alzheimer’s disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter Gayatri Devi is a nationally recognized neurologist specializing in memory disorders, including Alzheimer’s disease and related dementias. In this episode, Gayatri explains how to think about dementia as a spectrum—including Alzheimer’s disease, vascular dementia, Lewy body dementia, and mixed presentations—while exploring the evolving biology of amyloid, tau, and neuroinflammation and why brain pathology does not always correlate with symptoms. She discusses her approach to detecting subtle cognitive decline in high-functioning individuals, the role of biomarkers and APOE4 testing in asymptomatic patients, the benefits and risks of anti-amyloid therapies such as lecanemab and donanemab, and strategies for minimizing treatment-related complications. Gayatri also examines why some patients may stabilize or even improve with individualized care, the overlap among different dementia syndromes, and the relationship between menopause, estrogen, and cognition—including her concept of menopause-related cognitive impairment. Finally, she discusses how advances in early detection, AI-assisted monitoring, targeted therapies, and precision medicine are reshaping the future of dementia care. We discuss: Gayatri’s training and clinical focus, why dementia is a spectrum disease, and how personalized treatment is changing Alzheimer’s care [3:45]; How Alzheimer’s disease fits within the broader spectrum of dementia: diagnosis, biomarkers, and early pathophysiology [7:15]; The emerging role of neuroinflammation and viral infections in Alzheimer’s disease [13:30]; Gayatri’s comprehensive approach to evaluating cognitive decline in high-functioning patients [17:45]; Why forgetting names is usually normal and when word-finding problems become concerning [29:00]; Why women are at higher risk for Alzheimer’s disease and how menopause influences cognition [33:45]; The promise and limitations of blood-based biomarkers for diagnosing Alzheimer’s disease [40:15]; When preclinical Alzheimer’s screening is appropriate and how to interpret positive biomarker results [45:00]; Case study: early Alzheimer’s prevention in a highly-functional woman in her 50s with two copies of APOE4 [47:15]; Anti-amyloid therapies: balancing clinical benefit with ARIA risk using slow titration [51:45]; The aducanumab controversy, why it was discontinued, and why Gayatri would still choose it [1:00:00]; How anti-amyloid therapies cause ARIA, strategies for detecting and managing these complications, and how future therapies may improve safety and accessibility [1:03:30]; Two patient examples of exceptional responses to anti-amyloid therapy [1:12:30]; A multimodal approach to Alzheimer’s treatment: combination therapy, MRI-guided TMS, GLP-1 receptor agonists, and more [1:15:00]; Vascular dementia, Lewy body dementia, and the overlap with Alzheimer’s disease [1:21:00]; Lewy body dementia and Parkinson’s disease: distinguishing two alpha-synuclein disorders [1:26:45]; Risk factors for Lewy body dementia and what remains unknown [1:36:15]; Treating menopause-related cognitive impairment: hormone therapy, brain rehabilitation, and balancing breast cancer risk [1:38:45]; How biomarkers changed Gayatri’s perspective on the potential for Alzheimer’s patients to improve [1:47:15]; The future of Alzheimer’s care: AI, precision medicine, and personalized treatment [1:49:30]; and More. Connect With Peter on Twitter, […]

]]> b27561343db8eae95fb9e6b2935f46e7 https://primates.life/?p=75729 Mon, 06 Jul 2026 04:15:00 -0700 Building strength and muscle mass: how to optimize training, nutrition, and more for longevity (AMA #71 rebroadcast)View the Show Notes Page for This Episode Become […]

]]> 2851976bbd91360a8a6306c3f61976de https://primates.life/?p=75728 Mon, 06 Jul 2026 04:15:00 -0700 Building strength and muscle mass: how to optimize training, nutrition, and more for longevity (AMA #71 rebroadcast)View the Show Notes Page for This Episode Become a […]

]]> 2f9619119dc364e6f50b0395167d0f58 https://primates.life/?p=75730 Mon, 29 Jun 2026 04:15:00 -0700 #398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight lossView the Show Notes Page for This Episode […]

]]> c8a39ce53a68b11369421f262b58ad90 https://primates.life/?p=75732 Mon, 22 Jun 2026 04:15:00 -0700 #397 ‒ Endometriosis and adenomyosis: diagnosis, fertility, reproductive aging, and emerging treatments | Renato Tomioka, M.D., Ph.D.View the Show Notes Page for […]

]]> 0200bcba6ac4c6e0a902ba6198681c73 https://primates.life/?p=75735 Mon, 15 Jun 2026 04:15:00 -0700 #396 ‒ Breast cancer screening: understanding risk, deciding when to start and how often to screen, and choosing the right imaging strategyView the Show […]

]]> 0de61062e8755c79dfba1233cc5a5bf9 https://primates.life/?p=75734 Mon, 15 Jun 2026 04:15:00 -0700 #396 ‒ Breast cancer screening: understanding risk, deciding when to start and how often to screen, and choosing the right imaging strategyView the Show Notes […]

]]> 37539fb9b147415df9645f3ac4a17e98 https://primates.life/?p=75737 Mon, 08 Jun 2026 04:15:00 -0700 #395 – Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer’s disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D.View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter Tom Dayspring is a world-renowned lipidologist and one of the most thoughtful teachers in the field of lipid metabolism. In this episode, Tom returns to The Drive for a deep dive into the relationship between lipids and brain health, beginning with the fundamentals of cholesterol transport before exploring why the brain’s cholesterol system operates almost entirely independently from the rest of the body. Tom examines the roles of apoB, apoA-I, and especially apoE in cholesterol homeostasis, discusses how APOE genotype influences Alzheimer’s disease risk, and unpacks the complex links between cholesterol metabolism, amyloid, and tau pathology. He also reviews what is currently known—and still uncertain—about the effects of statins, ezetimibe, omega-3 fatty acids, and emerging CETP inhibitors on brain health and neurodegenerative disease risk. Although highly technical, this conversation provides an essential framework for understanding the nuanced relationship between lipid-lowering therapies, cardiovascular disease prevention, and neurodegenerative diseases in an area often clouded by misinformation. We discuss: The fundamentals of cholesterol transport in the body, and how peripheral cholesterol metabolism differs from cholesterol handling in the brain [2:45]; How cholesterol is transported through plasma and stored within cells, and why lowering LDL cholesterol does not deplete the body or brain of cholesterol [11:45]; How apoB particles drive atherosclerosis, why lowering lipids matters, and the factors that influence individual cardiovascular risk [20:00]; How the brain produces and transports its own cholesterol using apoE lipoproteins independently of circulating cholesterol and apoB-containing lipoproteins [29:00]; How apoB structure influences LDL receptor binding and LDL clearance [39:00]; How neurons acquire cholesterol from apoE-containing lipoproteins and why desmosterol serves as a unique marker of cholesterol synthesis in the brain [41:45]; The difference between the APOE gene and the apoE protein, the major APOE genotypes found in humans, and how APOE4 influences Alzheimer’s disease risk [48:45]; HDL function beyond cholesterol: immune function, protein cargo, and communication with the brain [53:30]; How APOE4-associated defects in brain cholesterol transport may promote Alzheimer’s disease: amyloid production, neuronal cholesterol homeostasis, and cholesterol clearance [58:00]; Statins and brain health: reviewing the evidence of the potential impact of statins on cognition and Alzheimer’s disease risk [1:09:00]; Desmosterol and 24S-hydroxycholesterol as biomarkers of brain cholesterol metabolism and statin effects [1:17:15]; Possible cognitive benefits of ezetimibe beyond lowering apoB [1:19:30]; EPA, DHA, and the evidence for omega-3 fatty acids in brain health [1:23:15]; Obicetrapib: an emerging CETP inhibitor with potential implications for both cardiovascular and brain health [1:31:00]; and More. Connect With Peter on Twitter, Instagram, Facebook and Yo […]

]]> 4f109fc926eb94b888f61e1ef98b0b2a https://primates.life/?p=75736 Mon, 08 Jun 2026 04:15:00 -0700 #395 – Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer’s disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D.View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter Tom Dayspring is a world-renowned lipidologist and one of the most thoughtful teachers in the field of lipid metabolism. In this episode, Tom returns to The Drive for a deep dive into the relationship between lipids and brain health, beginning with the fundamentals of cholesterol transport before exploring why the brain’s cholesterol system operates almost entirely independently from the rest of the body. Tom examines the roles of apoB, apoA-I, and especially apoE in cholesterol homeostasis, discusses how APOE genotype influences Alzheimer’s disease risk, and unpacks the complex links between cholesterol metabolism, amyloid, and tau pathology. He also reviews what is currently known—and still uncertain—about the effects of statins, ezetimibe, omega-3 fatty acids, and emerging CETP inhibitors on brain health and neurodegenerative disease risk. Although highly technical, this conversation provides an essential framework for understanding the nuanced relationship between lipid-lowering therapies, cardiovascular disease prevention, and neurodegenerative diseases in an area often clouded by misinformation. We discuss: The fundamentals of cholesterol transport in the body, and how peripheral cholesterol metabolism differs from cholesterol handling in the brain [2:45]; How cholesterol is transported through plasma and stored within cells, and why lowering LDL cholesterol does not deplete the body or brain of cholesterol [11:45]; How apoB particles drive atherosclerosis, why lowering lipids matters, and the factors that influence individual cardiovascular risk [20:00]; How the brain produces and transports its own cholesterol using apoE lipoproteins independently of circulating cholesterol and apoB-containing lipoproteins [29:00]; How apoB structure influences LDL receptor binding and LDL clearance [39:00]; How neurons acquire cholesterol from apoE-containing lipoproteins and why desmosterol serves as a unique marker of cholesterol synthesis in the brain [41:45]; The difference between the APOE gene and the apoE protein, the major APOE genotypes found in humans, and how APOE4 influences Alzheimer’s disease risk [48:45]; HDL function beyond cholesterol: immune function, protein cargo, and communication with the brain [53:30]; How APOE4-associated defects in brain cholesterol transport may promote Alzheimer’s disease: amyloid production, neuronal cholesterol homeostasis, and cholesterol clearance [58:00]; Statins and brain health: reviewing the evidence of the potential impact of statins on cognition and Alzheimer’s disease risk [1:09:00]; Desmosterol and 24S-hydroxycholesterol as biomarkers of brain cholesterol metabolism and statin effects [1:17:15]; Possible cognitive benefits of ezetimibe beyond lowering apoB [1:19:30]; EPA, DHA, and the evidence for omega-3 fatty acids in brain health [1:23:15]; Obicetrapib: an emerging CETP inhibitor with potential implications for both cardiovascular and brain health [1:31:00]; and More. Connect With Peter on Twitter, Instagram, Facebook and Yo […]

]]> 14af30baeb1cf53eb558623d725e7b00 https://primates.life/?p=75738 Mon, 01 Jun 2026 04:15:00 -0700 #394 ‒ Sleep pharmacology: the role of medications in healthy sleep, the promise of emerging therapies, and the evidence for common sleep supplementsView the […]

]]> 14af30baeb1cf53eb558623d725e7b00 https://primates.life/?p=75739 Mon, 01 Jun 2026 04:15:00 -0700 #394 ‒ Sleep pharmacology: the role of medications in healthy sleep, the promise of emerging therapies, and the evidence for common sleep supplementsView the […]

]]> aaf9213a9551345b5a45df6ec7d42364 https://primates.life/?p=75740 Mon, 25 May 2026 04:15:00 -0700 #393 ‒ AMA #85: A guide to medications and supplements: determining what to take, what to skip, and how to know if they’re working for youView the Show Notes […]

]]> aaf9213a9551345b5a45df6ec7d42364 https://primates.life/?p=75741 Mon, 25 May 2026 04:15:00 -0700 #393 ‒ AMA #85: A guide to medications and supplements: determining what to take, what to skip, and how to know if they’re working for youView the Show Notes […]

]]> 38f1d91a1521b72e6bbebd0e42632cd2 https://primates.life/?p=75743 Mon, 18 May 2026 04:15:00 -0700 #392 – Genetic testing: when it’s valuable, how to choose the right test, and what to do with the resultsView the Show Notes Page for This Episode Become a Member to […]

]]> 33c80241fe2b72c11de43a890b07ec83 https://primates.life/?p=75742 Mon, 18 May 2026 04:15:00 -0700 #392 – Genetic testing: when it’s valuable, how to choose the right test, and what to do with the resultsView the Show Notes Page for This Episode Become a Member to […]

]]> 062e0a8a7010bb1a32c2499f004a8087 https://primates.life/?p=75745 Mon, 11 May 2026 04:15:00 -0700 #391 ‒ Colorectal cancer screening: importance of early screening, colonoscopy as a screening and preventive tool, and how to build a personalized strategyVi […]

]]> c8546b2386d5ca879934909eaef0d9bc https://primates.life/?p=75744 Mon, 11 May 2026 04:15:00 -0700 #391 ‒ Colorectal cancer screening: importance of early screening, colonoscopy as a screening and preventive tool, and how to build a personalized strategyView […]

]]> a442015ea2492f789ede70dac6a41946 https://primates.life/?p=75747 Mon, 04 May 2026 04:15:00 -0700 #390 ‒ AMA #84: Family health history, preventing heart disease, metabolic health, strength training efficiency, dementia risk reduction, NAD supplements, and hydrationView the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter In this “Ask Me Anything” (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on how to think through real-world trade-offs and apply scientific evidence in practice. He explores how to build and interpret a meaningful family health history, how individual risk tolerance influences decisions around testing and treatment, and why heart disease remains poorly prevented despite available tools. He also examines whether it’s possible to carry excess body fat while remaining metabolically healthy, outlines the minimum effective dose for strength training for those with limited time, and discusses the habits and interventions most likely to reduce dementia risk. Additional topics include what evidence would need to emerge for him to reconsider his current stance on NAD-boosting supplements, and when hydration and electrolyte strategies are truly beneficial versus unnecessary. If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #84 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: Topics overview [1:15]; Using family history to assess disease risk: why it matters more than genetic testing and how to analyze it effectively [2:30]; Peter’s views that differ from conventional medicine: approaches to cardiovascular risk, cancer screening, nutrition, and more [10:30]; Risk tolerance in health decisions: weighing action versus inaction and avoiding low-benefit, high-risk interventions [16:00]; Why cardiovascular disease persists: delayed treatment, insufficient thresholds, and missed opportunities for early intervention [22:00]; Whether someone can be overweight yet metabolically healthy, and how fat distribution influences metabolic risk [26:45]; Strength training with limited time: how to maximize results with intensity and efficiency [30:00]; Designing a sustainable exercise routine: balancing volume, recovery, and enjoyment over time [34:45]; Reducing dementia risk: prioritizing exercise, sleep, and cardiometabolic health based on individual gaps [38:00]; Peter’s current skepticism toward NAD-related supplements and what evidence would be needed to change his view [40:45]; Hydration and electrolytes: factors that impact needs and when supplementation might be necessary [43:30]; and More. Connect With Peter on Twitter, Instagram, Facebo […]

]]> b782dc58b6cfe664fe73efe92bc1e568 https://primates.life/?p=75746 Mon, 04 May 2026 04:15:00 -0700 #390 ‒ AMA #84: Family health history, preventing heart disease, metabolic health, strength training efficiency, dementia risk reduction, NAD supplements, and hydrationView the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter In this “Ask Me Anything” (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on how to think through real-world trade-offs and apply scientific evidence in practice. He explores how to build and interpret a meaningful family health history, how individual risk tolerance influences decisions around testing and treatment, and why heart disease remains poorly prevented despite available tools. He also examines whether it’s possible to carry excess body fat while remaining metabolically healthy, outlines the minimum effective dose for strength training for those with limited time, and discusses the habits and interventions most likely to reduce dementia risk. Additional topics include what evidence would need to emerge for him to reconsider his current stance on NAD-boosting supplements, and when hydration and electrolyte strategies are truly beneficial versus unnecessary. If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #84 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: Topics overview [1:15]; Using family history to assess disease risk: why it matters more than genetic testing and how to analyze it effectively [2:30]; Peter’s views that differ from conventional medicine: approaches to cardiovascular risk, cancer screening, nutrition, and more [10:30]; Risk tolerance in health decisions: weighing action versus inaction and avoiding low-benefit, high-risk interventions [16:00]; Why cardiovascular disease persists: delayed treatment, insufficient thresholds, and missed opportunities for early intervention [22:00]; Whether someone can be overweight yet metabolically healthy, and how fat distribution influences metabolic risk [26:45]; Strength training with limited time: how to maximize results with intensity and efficiency [30:00]; Designing a sustainable exercise routine: balancing volume, recovery, and enjoyment over time [34:45]; Reducing dementia risk: prioritizing exercise, sleep, and cardiometabolic health based on individual gaps [38:00]; Peter’s current skepticism toward NAD-related supplements and what evidence would be needed to change his view [40:45]; Hydration and electrolytes: factors that impact needs and when supplementation might be necessary [43:30]; and More. Connect With Peter on Twitter, Instagram, Facebo […]

]]> be5c9bb72a2542bd2e41ccea41263699 https://primates.life/?p=75749 Mon, 27 Apr 2026 04:15:00 -0700 #389 – Thinking scientifically: why it’s hard, why it matters, and a practical toolkitView the Show Notes Page for This Episode Become a Member to Receive Exclusive […]

]]> a5ddc14731da0e7118f1424f3f2e020c https://primates.life/?p=75748 Mon, 27 Apr 2026 04:15:00 -0700 #389 – Thinking scientifically: why it’s hard, why it matters, and a practical toolkitView the Show Notes Page for This Episode Become a Member to Receive Exclusive […]

]]> 929e1a0901000557df9c9f3e9006235c https://primates.life/?p=75751 Mon, 20 Apr 2026 04:15:00 -0700 #388 — Prostate cancer screening: why current PSA guidelines are failing men and how modern tools improve early detection and save livesView the Show Notes Page for […]

]]> 935e064f3331892b843f589840c3aec1 https://primates.life/?p=75750 Mon, 20 Apr 2026 04:15:00 -0700 #388 — Prostate cancer screening: why current PSA guidelines are failing men and how modern tools improve early detection and save livesView the Show Notes Page for […]

]]> 5450fab1c6f811995063e6e64ffea03d https://primates.life/?p=75753 Mon, 13 Apr 2026 04:15:00 -0700 #387 – AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing fieldView the Show Notes Page for This Episode Become a Member to Receive […]

]]> d2bc54b3bbdc5bb8d6ecc04cf699ee7d https://primates.life/?p=75752 Mon, 13 Apr 2026 04:15:00 -0700 #387 – AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing fieldView the Show Notes Page for This Episode Become a Member to Receive […]

]]> 511ebba0163f578aea6bfcbf4f34454f https://primates.life/?p=75755 Mon, 06 Apr 2026 04:15:00 -0700 #386 – Aging clocks—what they measure, how they work, and their clinical and real-world relevanceView the Show Notes Page for This Episode Become a Member to […]

]]> b9a200101c7fc2ea82dc84252c8a855a https://primates.life/?p=75754 Mon, 06 Apr 2026 04:15:00 -0700 #386 – Aging clocks—what they measure, how they work, and their clinical and real-world relevanceView the Show Notes Page for This Episode Become a Member to Receive […]

]]> c07ee6742df8abe2fe4c55a1e2b6fc24 https://primates.life/?p=75757 Mon, 23 Mar 2026 04:15:00 -0700 #385 – AMA #82: Applying the tools of longevity in the real world: disease prevention, DEXA scans, artificial sweeteners, injury recovery, stability training, habit formation, protein intake and mTOR activation, and moreView the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter In this “Ask Me Anything” (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on practical decision-making and real-world application. He explores how health priorities and strategies should evolve across different decades of life, which chronic diseases are most challenging to manage and how to think about risk hierarchies, and which emerging interventions—beyond exercise—show the most promise for dementia prevention. Peter also breaks down the utility of wearables and explains how to use and interpret DEXA scans effectively. He discusses the challenges of behavior change and how to make healthy habits stick, along with training strategies for balance, stability, and injury resilience, drawing lessons from his own setbacks. Additional topics include high-protein diets and mTOR, how to weigh mechanisms versus outcomes, how to evaluate diet sodas and non-nutritive sweeteners in context, and a range of listener questions covering health fads, emotional health, and sleep routines. If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #82 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: Overview of episode topics, emphasizing the goal of providing actionable, real-world health guidance [1:30]; How health priorities and training strategies should evolve from early adulthood through older age [2:45]; Comparing the four major chronic diseases: which are most preventable, most uncertain, and most concerning [8:00]; Emerging strategies for dementia prevention: biomarkers, early detection, and new pharmacologic approaches [15:00]; How to use wearable data effectively: when it’s helpful, when it’s not, and how to avoid over-reliance [19:00]; DEXA scans: timing, interpretation, and limitations in body composition and bone density tracking [23:00]; Best practices for building sustainable health habits [30:15]; How to train your balance and stability [33:30]; How to recover from injuries and use setbacks to build strength and resilience [36:15]; High protein intake and the impact on mTOR: evaluating mechanisms versus real-world evidence on longevity [38:30]; Diet soda and artificial sweeteners: evaluating risks, benefits, and the importance of context [47:00]; How to balance enjoying life today with making choices that support long-term health and longevity [51:45]; and More. Connect With Peter on Twitter, Instagr […]

]]> 544cb20a1718998982349148bda2df1c https://primates.life/?p=75756 Mon, 23 Mar 2026 04:15:00 -0700 #385 – AMA #82: Applying the tools of longevity in the real world: disease prevention, DEXA scans, artificial sweeteners, injury recovery, stability training, habit formation, protein intake and mTOR activation, and moreView the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter In this “Ask Me Anything” (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on practical decision-making and real-world application. He explores how health priorities and strategies should evolve across different decades of life, which chronic diseases are most challenging to manage and how to think about risk hierarchies, and which emerging interventions—beyond exercise—show the most promise for dementia prevention. Peter also breaks down the utility of wearables and explains how to use and interpret DEXA scans effectively. He discusses the challenges of behavior change and how to make healthy habits stick, along with training strategies for balance, stability, and injury resilience, drawing lessons from his own setbacks. Additional topics include high-protein diets and mTOR, how to weigh mechanisms versus outcomes, how to evaluate diet sodas and non-nutritive sweeteners in context, and a range of listener questions covering health fads, emotional health, and sleep routines. If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #82 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: Overview of episode topics, emphasizing the goal of providing actionable, real-world health guidance [1:30]; How health priorities and training strategies should evolve from early adulthood through older age [2:45]; Comparing the four major chronic diseases: which are most preventable, most uncertain, and most concerning [8:00]; Emerging strategies for dementia prevention: biomarkers, early detection, and new pharmacologic approaches [15:00]; How to use wearable data effectively: when it’s helpful, when it’s not, and how to avoid over-reliance [19:00]; DEXA scans: timing, interpretation, and limitations in body composition and bone density tracking [23:00]; Best practices for building sustainable health habits [30:15]; How to train your balance and stability [33:30]; How to recover from injuries and use setbacks to build strength and resilience [36:15]; High protein intake and the impact on mTOR: evaluating mechanisms versus real-world evidence on longevity [38:30]; Diet soda and artificial sweeteners: evaluating risks, benefits, and the importance of context [47:00]; How to balance enjoying life today with making choices that support long-term health and longevity [51:45]; and More. Connect With Peter on Twitter, Instagram, […]

]]> 57d7755237287f909e5a28a29b9059c3 https://primates.life/?p=75759 Mon, 16 Mar 2026 04:15:00 -0700 #384 – Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer’s preventionView the Show Notes Page for This Episode […]

]]> 1fad318ca7115ebf51d7517d57fd79db https://primates.life/?p=75758 Mon, 16 Mar 2026 04:15:00 -0700 #384 – Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer’s preventionView the Show Notes Page for This Episode […]

]]> d36f1fd63d9d410506e89bff605a9940 https://primates.life/?p=75760 Mon, 19 Jan 2026 05:15:00 -0700 #380 ‒ The seed oil debate: are they uniquely harmful relative to other dietary fats? | Layne Norton, Ph.D.View the Show Notes Page for This Episode Become a […]

]]> 04d0f6aef0704c845c837be39e2b5e3b https://primates.life/?p=75763 Mon, 12 Jan 2026 05:15:00 -0700 #379 – AMA #79: A guide to cardiorespiratory training at any fitness level to improve healthspan, lifespan, and long-term independenceView the Show Notes Page for This […]

]]> e41a10e8f12f96eb3a4a0f30ade0bde0 https://primates.life/?p=75762 Mon, 12 Jan 2026 05:15:00 -0700 #379 – AMA #79: A guide to cardiorespiratory training at any fitness level to improve healthspan, lifespan, and long-term independenceView the Show Notes Page for This […]

]]> b77a5671ea02147fa97ce2e4c2bd7260 https://primates.life/?p=75765 Mon, 05 Jan 2026 05:15:00 -0700 #378 ‒ Women’s health and performance: how training, nutrition, and hormones interact across life stages | Abbie Smith-Ryan, Ph.D.View the Show Notes Page for […]

]]> dc592ea5298ca870025c54b357985d49 https://primates.life/?p=75764 Mon, 05 Jan 2026 05:15:00 -0700 #378 ‒ Women’s health and performance: how training, nutrition, and hormones interact across life stages | Abbie Smith-Ryan, Ph.D.View the Show Notes Page for This […]

]]> d48ecb98b89104808aaf7c080ca024f2 https://primates.life/?p=75767 Mon, 29 Dec 2025 05:15:00 -0700 Building & Changing Habits | James Clear (#183 rebroadcast)View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive […]

]]> 312f8d8af552f9657ebe64f52e348a17 https://primates.life/?p=75766 Mon, 29 Dec 2025 05:15:00 -0700 Building & Changing Habits | James Clear (#183 rebroadcast)View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive […]

]]> 9767c73e5cc2a8f88a917eb76040e673 https://primates.life/?p=75769 Mon, 22 Dec 2025 05:15:00 -0700 #377 ‒ Special episode: Understanding true happiness and the tools to cultivate a meaningful life—insights from past interviews with Arthur BrooksView the […]

]]> 1ffa913d899cacfc39f5900ca1a47073 https://primates.life/?p=75768 Mon, 22 Dec 2025 05:15:00 -0700 #377 ‒ Special episode: Understanding true happiness and the tools to cultivate a meaningful life—insights from past interviews with Arthur BrooksView the […]

]]>